{
    "2018-02-14": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Merck & Co.’s Revenues in 4Q17",
                "features": {
                    "keywords": [
                        "Merck",
                        "Revenues",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Taltz",
                        "New Data",
                        "Immunology",
                        "AAD Annual Meeting"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "immunology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Lilly's Taltz Positive in Phase III Label Expansion Study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Taltz",
                        "Phase III",
                        "Label Expansion",
                        "Study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "immunology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Merck (MRK) Halts Another Late Stage Study on Alzheimer's",
                "features": {
                    "keywords": [
                        "Merck",
                        "Alzheimer's",
                        "Late Stage Study",
                        "Halts"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "neurology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Bristol-Myers Squibb’s Valuation after Its 4Q17 Earnings",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Valuation",
                        "4Q17 Earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Merck (MRK) Halts Another Late Stage Study on Alzheimer's",
                "features": {
                    "keywords": [
                        "Merck",
                        "Alzheimer's",
                        "Late Stage Study",
                        "Halts"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "neurology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Lilly's Taltz Positive in Phase III Label Expansion Study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Taltz",
                        "Phase III",
                        "Label Expansion",
                        "Study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "immunology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "How Did Pfizer’s Viagra and Lyrica Perform in 2017?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Viagra",
                        "Lyrica",
                        "Performance",
                        "2017"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Changes in Bristol-Myers Squibb’s 4Q17 Profitability",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Profitability",
                        "4Q17"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Free Research Report as Eli Lilly’s Quarterly Revenue Jumped 6%; Adjusted EPS Jumped 20%",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Revenue",
                        "Jumped",
                        "Adjusted EPS",
                        "20%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}